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Enhanced gastrointestinal absorption of aluminum
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Enhanced gastrointestinal absorption of aluminum in uremic rats. To
investigate the possibility of enhanced gastrointestinal absorption of
aluminum in uremia, we measured the urinary aluminum excretion of
rats following an oral load of 11 mg aluminum. Rats, in which uremia
had been established by the remnant kidney model, excreted 1.5 to
2.2-fold higher amounts of aluminum in their urine over a collection
period of five days compared with their controls. Within this period of
time up to 0.17 0.08%of the oral dose of aluminum was recovered in
the urine of the uremic animals. Serum concentrations of aluminum
were significantly elevated five hours after ingestion of aluminum, but
this increase was similar in rats with normal or reduced renal function.
Uremic rats excreted significantly less aluminum during the first 24
hours after iv. administration of 15 jsg aluminum if the data were
corrected for the higher baseline excretion rates. The excretion rate
showed a negative correlation with the serum creatinine. Selective
parathyroidectomy had no effect on the pattern or amount of urinary
aluminum excretion after an oral load in either uremic rats or in rats
with normal renal function. We conclude that the gastrointestinal
absorption of aluminum is increased in uremic rats, and that parathy-
roid hormone has no detectable effect on the magnitude of aluminum
absorption, regardless of the renal function in this model.
AlUminum intoxication in patients with chronic renal failure
undergoing hemodialysis is the most probable cause of dialysis
encephalopathy [1, 2] and may be of major importance in the
pathogenesis of microcytic anemia [3—5] and low turnover
osteomalacia which is refractory to vitamin D therapy [6—9].
Aluminum contaminated dialysate has been the predominant
source of aluminum loading; however, there have been reports
of aluminum intoxication in patients with reduced renal func-
tion not requiring hemodialysis and in patients dialyzed in areas
with a low aluminum content of the water [10—13]. It has been
assumed that the combination of large oral loads of aluminum in
the form of aluminum-containing, phosphate-binding gels and
reduced ability to excrete aluminum because of renal insuffi-
ciency are involved in the pathogenesis of these cases. How-
ever, since tissue aluminum concentrations have frequently
been found to be increased in non-dialyzed uremic patients who
have not had a history of ingesting aluminum-containing, phos-
phate-binding gels [14], it seems possible that aluminum absorp-
tion from ordinary dietary sources might be enhanced in the
uremic state.
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The present study investigates whether the state of uremia
alters the gastrointestinal absorption of aluminum and whether
the function of the parathyroid glands modifies this process in
rats with a remnant kidney.
Methods
Twenty-eight 8-week-old, male Sprague-Dawley rats (Simonsen
Mill Rendering Plant, Quimby, Iowa, USA) weighing 300 to 400
g were divided into two groups. In the first group (N = 15),
uremia was established by uninephrectomy (Nx) and use of a
remnant kidney according to a previously described protocol
[15]. The remaining rats served as controls. During the subse-
quent study, uremic rats had free access to food ("Rodent
Blox", Wayne Co. Chicago, Illinois, USA) and water. Uremic
rats and controls were pair weighed twice a week and food was
restricted for the rats in the control group so that the weight
gains in the uremic and control groups were parallel. Three
weeks after Nx, the uremic group was split into two subgroups:
a moderately uremic group (N = 8) consisting of rats with
moderate elevations of the serum creatinine (1.21 0.08 mg/dl)
and a severely uremic group (N = 7) of rats with a more marked
rise in serum creatinine (1.87 0.29 mg/dl). All three groups
were given an oral load of 11 mg aluminum administered as
A1C13 in 1 ml of deionized water by gastric lavage.
In separate experiments, six uremic rats, chosen at random,
and five controls underwent selective parathyroidectomy (PTX).
The effectiveness of PTX was documented by requiring the
plasma calcium to be 7 mg/dl or less. It has been shown that
thyroid function is not affected by this procedure [16]. PTX
rats, as well as their controls, received deionized water con-
taining 2% Ca-lactate and 1% sucrose to control hypocalcemia
in the former group. The remaining uremic non-PTX rats were
matched by weight and serum creatinine to serve as controls.
Similarly, the non-PTX rats with normal renal function served
as controls for PTX rats with normal renal function. All four
groups received two separate oral aluminum loads separated by
a period of 20 to 25 days. Food was withdrawn 16 hours before
the oral aluminum load and returned 8 hours afterwards. Prior
to the oral administration of aluminum, 24-hour urine collec-
tions were obtained at least twice; subsequently, urine was
collected daily over a period of five days.
In a final study, 8 uremic and 8 control rats (non-PTX)
received 15 g aluminum i.v. in 0.5 ml of saline as a bolus three
weeks following the oral aluminum load. Fifteen jg of alumi-
num were chosen to approximate the systemic load of alumi-
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Table 1. Urinary aluminum excretion over a period of five days following an oral load of 11 mg aluminum in two groups of uremie rats, and in
one control group
Group N
Serum creatinine
mg/d!
Weight
g
Urine aluminum pg/day
Pre-load
Post-load
I day
Post-load total
excretion
5 days
Moderately uremic
Severely uremic
Control
8
7
8
1:21 0.08
1.87 0.29
0.75 0.19
358 27
338 18
330 26
0.61 0.35
0,38 0.17
0.40 0.54
7.47 4.32
6.93 2.55
4.33 1.40
14.08 6.38
15.60 5.41a
9.23 2.21
a P < 0.05 vs. control
Statistical analysis by Dunnett's test
0
1 2 3 4 5
pre-load post-load Time, days
FIg. 1. Pattern of urinary aluminum excretion following an oral load of
11 mg Al. Values are mean SD. The solid line represents the values of
the severely uremic rats, the broken line represents the values of the
control animals.
num absorbed from the oral load. Seventy-two hours prior to
aluminum administration, animals were housed individually in
metabolic (Nalgene) cages for urine collections and received
deionized water (aluminum content less than 5 gIliter) as
drinking water. Rats receiving deionized water with 2% Ca-
lactate and 1% sucrose (aluminum content less than 5 g/1iter)
remained on it save except for a brief period of one hour prior
to and two hours after the aluminum administration when
access to drinking water was interrupted.
Analysis of aluminum in serum and urine was performed on a
flameless atomic absorption spectrophotometer (Perkin-Elmer
305B, Norwalk, Connecticut, USA) using a previously reported
method [171. Calcium was determined by atomic absorption
(Perkin-Elmer 370). Creatinine was measured by an autoana-
lyzer (Beckman Creatinine Analyzer II, Beckman Instruments,
Fullerton, California, USA). Statistical analysis was performed
using paired and unpaired Student's t-test, Dunnett's test for
comparing several treatments with a control [18], one-way
analysis of variance, and linear regression. Results are ex-
pressed as mean 1 standard deviation.
Results
After 11 mg of aluminum were administered orally to uremic
and control rats, there was, on the average, a 14-fold increase of
urinary aluminum excretion within the following 24 hours
compared with baseline excretion rates (Fig. 1). Within five
days, between 6.27 .rg and 23.58 g of aluminum were recov-
ered in the urine of individual rats (0.06 to 0,21% of the load)
with approximately 48% of this amount being excreted on the
first day. There was a clear tendency for both uremie subgroups
to excrete more aluminum than the controls during the first 24
hours as well as during the following days. At the fifth day, the
control animals had almost reached the baseline excretion rates
while the values of both uremic subgroups remained somewhat
higher. The overall urinary excretion of aluminum after five
days was significantly higher in uremic rats with markedly
elevated serum creatinine compared with the controls (15.60
5.41 p.g vs. 9.23 2.21 g, P < 0.05) (Table 1). The same
tendency towards a higher urinary aluminum in moderately
uremic rats just failed to achieve statistical significance. At that
time serum creatinine values were 1.21 0.08 mgldl and 1.87
0.29 mg/dl in moderately uremic and severely uremic rats,
respectively (controls 0.75 0.19 mg/dl, P < 0.001). The body
weights of the uremic animals as compared with the controls
were not significantly different.
Five uremic rats and six control rats underwent selective
PTX. After a second oral load with aluminum the pattern of
urinary excretion was similar to that found after the first load.
Apparently, PTX had no influence on the amount of aluminum
excreted in the urine, in either uremic rats or in rats with normal
renal function (Table 2). Uremic rats, no matter whether they
had undergone PTX or not, excreted significantly more alumi-
num than their control groups. Uremic PTX rats and control
PTX rats excreted 14.53 5.89 ig and 7.30 1.57 p.g A115
days, respectively (P < 0.025); uremic non-PTX rats and
non-PTX controls excreted 18.56 8.48 p.g vs. 8.54 2.46 p.g
Al/S days (P < 0.005). No significant differences in urinary
aluminum were observed between either uremic PTX and
non-PTX rats or PTX and non-PTX rats with normal renal
function.
Five hours after the oral load the serum concentrations of
aluminum in uremic and control rats (both non-PTX) increased
significantly (Table 3). However, there was no difference in the
magnitude of this increase between both groups, Twenty-four
hours after aluminum administration serum concentrations had
dropped back to baseline values. Pre-load values and 24-hour
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Table 2. Urinary aluminum excretion over a period of five days following an oral load of 11 mg aluminum
Group N
Serum creatinine
mg/dl
Weight
g
Urine aluminum .g/day
Pre-load
Post-load
I day
Post-load total
excretion
5 days
Uremic
Uremic PTX
Control
Control PTX
8
6
8
5
1.15 0.24
1.25 0.33
0.74 0.19
0.74 0.09
377 29
364 48
345 25
359 9
0.76 0.30
0.67 0.38
1.25 0.86
0.40 0.27
9.08 3.88
8.15 3.71
3.29 1.53
2.91 1.06
18.56 8.48a
14.53 589b
8.54 2.46
7.30 1.57
a P < 0.005 vs. control
b P < 0.025 vs. control PTX
Statistical analysis was by one-way analysis of variance. Comparison of rats with uremia, rats with uremia plus PTX, rats with normal renal
function (control), and rats with normal renal function plus PTX (control plus P1'X)
Aluminum concentration in serum p.g/liter
Post-load Post-load
Group N Pre-load 5 hours 24 hours
Uremic 8 5±3 13±8a 4±2
Control 6 6 3 13 5b 7 3
Table 4. Excretion of aluminum in urine of uremic rats and control
rats following an intravenous load of 15 ig aluminum
Group
Urine aluminum j.g/day
One day Two day Three day
N Pre-load post-load post-load post-load
Uremic
Control
8 1.86 0.60a 7.47 1.64 2.22 0.62 1.93 0.87
8 0.96 0.47 9.39 2.59 1.74 0.72 0.98 0.56
post-load values displayed no difference between uremic rats
and their controls.
Following intravenous administration of 15 g aluminum,
uremic rats (non-PTX) excreted 7.47 1.64 j.tg Al during the
first 24 hours in their urine vs. 9.39 2.59 g in the control
group (P = NS), and after two days the total amount of
aluminum recovered was 9.69 1.70 and 11.13 2.98 g,
respectively (Table 4). However, the baseline excretion rates of
urinary aluminum in the uremic rats before the i.v. aluminum
load were significantly higher than in the controls (1.86 0.60
vs. 0.96 0.47 g Al124 hr, P < 0.0025). If the post-load data
were corrected by subtracting the pre-injection excretion rates
for individual rats in both groups, uremic animals excreted
significantly less aluminum during the first 24 hours (SAl 5.61
1.70 gI24 hr vs. 8.43 2.27 g/24 hr, P < 0.02). Within three
days, 62% (zAl 9.23 2.25 .tg) of the i.v. dose was recovered
in the urine of the controls versus 40% (AAI 6.04 2.28 g) in
the uremic group (P < 0.02). During the 24 hours following the
i.v. administration of aluminum there was a significant negative
correlation between serum creatinine and the increase in un-
nary aluminum in the uremic rats (r = —0.66, P <0.05) (Fig. 2).
This suggests that as renal functional impairment progressed
there was less capability to excrete an intravenous aluminum
load,
Discussion
Early studies in humans estimated that dietary intake of
aluminum was 10 to 90 mg/day [19, 20], but later investigations
indicated there is an intake of only 2 to 3 mg/day [14, 21]. Still,
no matter how much aluminum is ingested, little is absorbed.
This perception is based on the fact that tissue aluminum
concentrations are normally quite low (total body aluminum
less than 35 mg) and do not increase with aging [17]. Moreover,
it has been assumed that any aluminum that is absorbed in
healthy individuals is eliminated in the urine, thus maintaining
the low body burden of this element [22, 23]. Normal urine
aluminum excretion has been reported to be quite low and to
vary between 13 7 to 65 85 pg/day [24—26]. Following large
oral loads of aluminum, urinary aluminum has been found to
increase 10- to 20-fold [21, 24, 261. The question arising from
Table 3. Serum concentrations of aluminum before and after an oral
load of 11 mg aluminum in rats with chronic renal failure and a
control group with normal renal function 8
a P < 0.02 vs. pre-loadb P < 0.01 vs. pre-load
Statistical analysis by Student's t-test for paired samples
2 = —0.66
0
0.5 1.0
a P < 0.0025 vs. pre-load of controls
Statistical analysis by Student's t-test for unpaired samples
1.5 2.0
Serum creatinine, mg/d!
Fig. 2. Relationship between the serum creatinine and the increase in
urinary aluminum (1Al) during the first 24 hours after i.v. administra-
tion of 15 tgAl in eight uremic rats. zAl was calculated by subtracting
the pre-load urinary aluminum excretion rates from the post-load
excretion rates.
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these studies is not whether some of this excess aluminum is
absorbed but if all the absorbed aluminum is eliminated through
the kidney. Early balance studies suggested that as much as 23
to 313 mg/day of aluminum was absorbed and retained in
normal individuals given 1 to 3 grams of supplemental alumi-
num daily [21, 27, 28]. However, these studies must be inter-
preted with some caution, for the oral loads given are so large
that small differences can barely be noticed. Furthermore, there
has been only one case report of increased, tissue aluminum
concentrations in an individual with normal renal function
whose only aluminum exposure was through oral sources [24].
This casts further doubt on the validity of these studies. In
addition, even uremic patients who have been taking large oral
loads of aluminum for years do not have body burdens of
aluminum increased nearly to the extent that would result from
such large positive aluminum balances as reported above [17].
More recent studies would suggest that when aluminum intake
is moderately increased little aluminum is actually absorbed
(approximately 0.1%), and this small amount is eliminated by
the kidney [17, 26].
Academically speaking, even if all of the aluminum normally
excreted by the kidney were retained over a year's period, total
body aluminum content would still be increased only around 6
mg. Bone aluminum alone has been found to be increased by up
to 320 mg in non-dialyzed uremic patients and 85% of non-
dialyzed uremic patients have been found to have elevated bone
and/or liver aluminum concentrations [14, 29]. This suggests
that either all of these patients have received supplemental oral
aluminum intake or that aluminum absorption, from the usual
sources, is enhanced in the uremic state.
The contention that aluminum absorption is enhanced in the
uremic state is supported by the present study. In two separate
studies, uremic rats were found to excrete more aluminum in
their urine than control animals following an oral aluminum
load. There was a tendency for aluminum excretion to be
further enhanced by the greater severity and chronicity of the
uremic state. Following the oral aluminum load in both control
and uremic animals, approximately 50% of the increased urine
aluminum was excreted in the first 24 hours, and by the fifth day
urine aluminum had largely returned to baseline values. Assum-
ing that the kidney is the major organ responsible for eliminat-
ing aluminum, this pattern is consistent with the view that little
of the absorbed aluminum is retained in the body after a single
oral dose.
An apparent conflict with the above observation is the finding
that uremic rats, but not controls, studied three weeks after
administration of a second oral aluminum load had significantly
higher, baseline urinary aluminum excretion rates than those
found in the earlier studies, a finding which could indicate slow
mobilization of previously bound aluminum. A more likely
possibility, however, is that just as uremic rats absorb more
aluminum following an oral aluminum load so do they also
absorb more aluminum from their rat chow, which normally
contains 49 g Al/g; this, in turn, is reflected in their baseline
urinary aluminum. That this condition was not found in animals
in the initial study with a shorter duration of uremia is consist-
ent with the idea that enhanced absorption of aluminum in
uremia is more related to the duration of uremia than to its
severity.
There is no available isotope with which to study aluminum
absorption; thus, indirect techniques, such as measuring changes
in urinary excretion or tissue concentrations of aluminum, have
to be employed. These methods obviously have their limita-
tions.
One possible explanation for the augmented renal excretion
of aluminum following an oral load in uremic animals is en-
hanced elimination as a result of altered tissue and plasma
binding in the uremic state. To study this possibility, uremic
and control rats were given an intravenous dose of aluminum
similar to that excreted in the urine following an oral load. The
uremic rats actually excreted less aluminum following this
injection than the control animals, suggesting that tissue binding
of aluminum was greater in the uremic group, probably as a
result of delayed excretion due to compromised renal function.
Another interesting finding was that following intravenously
administered aluminum, there was an inverse correlation be-
tween urine aluminum and serum creatinine, whereas such a
correlation was not found following an oral aluminum load.
Urine aluminum following an oral load was as high, if not
higher, in uremic animals with marked renal impairment as in
those animals with modest renal impairment, and this might
suggest that urine aluminum excretion may underestimate alu-
minum absorption in the more advanced uremic state. The
implication would be that as renal failure progresses there is
even further enhancement of aluminum absorption than that
reflected by the renal excretion of this element.
We were not able to demonstrate differences in the serum
concentrations of aluminum between rats with normal and
reduced renal function. In both groups the five-hour post-load
values were significantly higher than the pre-load values, and
the 24-hour post-load values had dropped back to the baseline.
However, it is possible that peak blood concentrations occurred
prior to the five hour samples, thus explaining why serum
values were not higher in the uremic group. In addition, lack of
sensitivity of the analytical method for measuring serum alumi-
num and potential for contamination from tail vein puncture
precludes our ability to show minor differences in serum values,
which would explain the increased urinary excretion of this
element in uremic animals. Increased aluminum concentrations
in plasma and several tissues are a consistent finding in patients
with chronic renal failure [29—33]. The majority of these mea-
surements have been made in patients with long-standing renal
failure requiring hemodialysis and receiving aluminum-contain-
ing antacids. Because of the time period extension, the present
animal model does not resemble this particular situation, and
actual differences in the post-load serum concentrations be-
tween uremic and normal rats may have been too small to be
detectable. Additionally, there may be a blunted increase in
serum concentrations in uremic rats resulting from augmented
tissue binding. Taken together, measurements of 24-hour uri-
nary aluminum excretion appear to be more sensitive than
measurements of serum aluminum concentrations to quantify
the magnitude of the intestinal absorption of aluminum from
single oral loads [34].
Interrelations between the function and secretion of parathy-
roid hormone (PTH) and aluminum have been suggested. Alu-
minum reduced PTH secretion by parathyroid cells in vitro [35],
and aluminum may accumulate preferentially in the parathyroid
glands [361, though other investigators have not been able to
substantiate these findings [37, 38]. It has also been claimed that
Intestinal absorption of Al in uremic rats 825
PTH may promote aluminum absorption from the gut [39, 401.
On the basis of the present data we were unable to confirm this
hypothesis: Parathyroidectomy had no effect on the amount of
urinary aluminum following an oral load in either uremic
animals or in controls. Further indirect evidence for the lack of
an effect of PTH on aluminum absorption is the finding that
PTH levels in uremic patients correlate neither with plasma nor
with bone aluminum concentrations [41—431. In fact, generally,
patients with the highest bone aluminum concentrations tend to
have the lowest serum PTH levels [44].
Normally, aluminum is poorly absorbed from the gut, which
is an actual benefit to the individual because of the potential
systemic toxicity of this element. But this barrier to the
absorption of aluminum appears to be compromised in the
uremic state. Although the reason is unclear, uremia does lead
to a variety of morphological changes in the entire gastrointes-
tinal tract which may affect its integrity [45—47]. Some of these
histological changes in the upper gastrointestinal tract are partly
vitamin D-dependent, although it is not entirely clear how
vitamin D therapy might affect aluminum absorption [48, 49].
Since aluminum has been shown to be more soluble in an acid
milieu, it has been suggested that gastric pH may have an effect
on aluminum absorption [34, 50]. Gastric acidity has been
reported to be increased in chronic renal failure, but this has not
been a consistent finding [5 1—55].
At present, we can only conclude that neither site nor
mechanism for the absorption of aluminum have been defined
definitely, and further investigations will be necessary to eval-
uate the cause of the apparently enhanced aluminum absorption
in uremia.
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